TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9610942
Drug: Zolpidem with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem with alcohol (0.75 g ethanol/kg b.wt.)
Study: 7821190
Drug: 4 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 injections per day with a pen injector
Study: 26520004
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg
Study: 21153402
Drug: Immunoparalysis (TNFα
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoparalysis (TNFα response <200 pg/mL)
Study: 14532998
Drug: One arterial
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One arterial infusion of cisplatin
Study: 11070752
Drug: Moclobemide (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (maximum dose 600 mg per day)
Study: 11070752
Drug: Amitriptyline (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (maximum dose 150 mg per day)
Study: 8968702
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk product (200 ml daily)
Study: 8968702
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 ml daily)
Study: 1621746
Drug: Amoxicillin/clavulanate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (500 mg three times daily)
Study: 7570411
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg three times daily)
Study: 24454970
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of AmBisome (7 times 3 mg/kg on days 1-5, 14, and 21)
Study: 24454970
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of AmBisome 10 mg/kg
Study: 24454970
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of AmBisome
Study: 10385721
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg)
Study: 18058622
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 supplementation (1000 IU per orally five days per week for 10 weeks)
Study: 16219099
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of pre-hospital emergency pathway (training module and administration of the guideline)
Study: 3139830
Drug: Flunarizine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (20 mg)
Study: 26867076
Drug: Sertraline therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline therapy (50-200 mg daily)
Study: 24582532
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist use
Study: 20456735
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose (60 mg)
Study: 10551154
Drug: Scaling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling with adjunctive antimicrobial therapy
Study: 10512386
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received supportive periodontal therapy at 3, 6, 9, 12, 18, and 24 months
Study: 782679
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aerosol (BDA), 50 mug four times daily in each nostril
Study: 16936418
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous and intracoronary administration of nicorandil (Group B)
Study: 16936418
Drug: No nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No nicorandil administration (Group C)
Study: 4044346
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose per fraction radiotherapy at 9 Gy X 3
Study: 4044346
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose per fraction radiotherapy at 5 Gy X 8 twice weekly
Study: 27871505
Drug: Sugammadex (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2-4 mg · kg‐1) after deep neuromuscular block with 0.6 mg · kg‐1 rocuronium
Study: 27871505
Drug: Neostigmine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (50 μg · kg‐1) after shallow neuromuscular block with 0.45 mg · kg‐1 rocuronium
Study: 27871505
Drug: Sugammadex (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2-4 mg · kg‐1)
Study: 27871505
Drug: Neostigmine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (50 μg · kg‐1)
Study: 22820319
Drug: Palivizumab (one-monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab (one-monthly intramuscular injections during RSV season, minimum of 2 injections)
Study: 18827610
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan (OT) with best supportive care
Study: 2198072
Drug: Exploratory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exploratory therapy (relationship-oriented)
Study: 2198072
Drug: Prescriptive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptive therapy (cognitive/behavioural)
Study: 8563662
Drug: Eight sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight sessions of therapy
Study: 2198072
Drug: 16 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 sessions of therapy
Study: 387000
Drug: DL-phenylalanine (150-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-phenylalanine (150-200 mg/24 h)
Study: 387000
Drug: Imipramine (150-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (150-200 mg/24 h)
Study: 31870394
Drug: Community-based preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based preventive intervention including screening for hypertension, diabetes, and stroke, followed by referral to a mobile outreach clinic, guideline-based treatment, monthly home visits by CHWs for medication compliance, and counseling on reducing salt consumption and quitting tobacco and alcohol.
Study: 25673557
Drug: Milk (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (500 ml) - Male
Study: 25673557
Drug: Carbohydrate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (500 ml) - Female
Study: 25673557
Drug: Carbohydrate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (500 ml) - Male
Study: 19317162
Drug: Longbishu Capsule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longbishu Capsule, 0.9 g each time, taken twice a day for 4 weeks
Study: 12573743
Drug: Compliance to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance to prescribed radiation therapy schedule
Study: 12573743
Drug: Recent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent treatment compliance
Study: 2856778
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (hydrochlorothiazide + triamterene)
Study: 18525001
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (among patients not receiving erythropoiesis-stimulating agents)
Study: 18525001
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (among patients receiving erythropoiesis-stimulating agents)
Study: 1996436
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron
Study: 8360128
Drug: Mupirocin nasal
Normalized name: mupirocin Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin nasal ointment
Study: 3121830
Drug: High heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High heparin dose (137.3 U/day) during 15-hour lipid infusion
Study: 3121830
Drug: Low heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low heparin dose (24 U/day) infused over 24 hours
Study: 3121830
Drug: Both heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both heparin doses at either infusion rate
Study: 27696933
Drug: High-flavanol and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavanol and high-theobromine (HFHT) chocolate (30 grams daily for 12 weeks)
Study: 27696933
Drug: Low-flavanol and
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavanol and low-theobromine (LFLT) chocolate (30 grams daily for 12 weeks)
Study: 20380782
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI) pharmacotherapy
Study: 16060712
Drug: tretinoin emollient
Normalized name: Tretinoin Emollient Topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: tretinoin emollient cream 0.05%
Study: 7822066
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg taken four times daily)
Study: 16276136
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control (no direct thrombin inhibitors)
Study: 12362931
Drug: Erythromycin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (800 mg per day)
Study: 12362931
Drug: Clarithromycin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (400 mg per day)
Study: 31346969
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with vitamin D 300,000 IU; n=46
Study: 12747344
Drug: Oral pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pentazocine (100 mg) plus lorazepam (1 mg)
Study: 1619098
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with therapeutic empathy
Study: 1619098
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with homework compliance
Study: 29401473
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group writing daily events for 30 days
Study: 16085513
Drug: Nicotine replacement,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine replacement, antidepressants, and psychological interventions
Study: 9880175
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation treatment of 3 x 3.3 Gy
Study: 9880175
Drug: NSAID therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID therapy (3 x 50 mg of diclofenac per day for 3 weeks)
Study: 7973766
Drug: Single-agent vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent vinorelbine
Study: 19323801
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg riboflavin
Study: 19323801
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg riboflavin
Study: 15451219
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg once a day
Study: 19720924
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg twice a day
Study: 11376307
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral nicorandil 3 times daily (n = 15)
Study: 9763724
Drug: Artesunate (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (700 mg for 5 days)
Study: 7924750
Drug: IFN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN treatment
Study: 3047220
Drug: Sucralfate emulsion
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate emulsion (1 g four times daily)
Study: 2035471
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg beta-carotene per day
Study: 18928339
Drug: Aripiprazole (2-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (2-15 mg/day)
Study: 26633622
Drug: TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitors
Study: 18001541
Drug: Ulinastatin (UTI)
Normalized name: phenazopyridine hydrochloride Oral Tablet [UTI Relief]
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (UTI) treatment in Group A
Study: 18001541
Drug: Ulinastatin (UTI)
Normalized name: phenazopyridine hydrochloride Oral Tablet [UTI Relief]
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (UTI) treatment in Group C
Study: 15112008
Drug: 2.5% suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% suspension concentrate (SC) deltamethrin applied with manual compression sprayers
Study: 15112008
Drug: 2.5% suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% suspension concentrate (SC) deltamethrin applied with power sprayers
Study: 29794782
Drug: Intra-coronary administration
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-coronary administration of tirofiban through aspiration catheter
Study: 29794782
Drug: Intra-coronary administration
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-coronary administration of tirofiban through guiding catheter
Study: 27489202
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 3% gel
Study: 19834806
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate solutions (OSPS)
Study: 16201292
Drug: Yaoliuan capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yaoliuan capsule
Study: 8829933
Drug: Propofol anaesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anaesthesia (induction: 2-3 mg kg-1, maintenance: 6-10 mg kg-1 h-1)
Study: 6527752
Drug: disulfiram (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: disulfiram (400 mg/day) for 6 days
Study: 2192383
Drug: placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets
Study: 6527752
Drug: propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (80 mg/day) for 4 weeks
Study: 15655139
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of efalizumab weekly
Study: 6969348
Drug: Co-trimoxazole and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole and lactobacilli preparation
Study: 30446826
Drug: Three PVB
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three PVB injections
Study: 30446826
Drug: Five PVB
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five PVB injections
Study: 21346517
Drug: music and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: music and art therapy and psychomotor activity
Study: 2042788
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (30 ng/kg/min)
Study: 17250535
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.005 mg/mL
Study: 17250535
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05 mg/mL
Study: 17250535
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.5 mg/mL
Study: 15047241
Drug: Liposomal lurtotecan
Normalized name: Lurtotecan
DrugBank: Lurtotecan (DB12222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal lurtotecan at a dose of 2.4 mg/m(2) on Days 1 and 8 of a 21-day cycle
Study: 9096985
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg q.d. BTS 67,582
Study: 9096985
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg b.i.d. BTS 67,582
Study: 9096985
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg b.i.d. BTS 67,582
Study: 3515923
Drug: Acetaminophen alone
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen alone or in combination with oxycodone
Study: 3515923
Drug: Acetaminophen/oxycodone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen/oxycodone and lidocaine
Study: 31133457
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (conventional subcutaneous insulin therapy)
Study: 30387043
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 400-1200 mg/day
Study: 24661523
Drug: Calf pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf pulmonary surfactant (50 mg/kg) within 6 hours after admission (Treatment group 1)
Study: 24661523
Drug: Calf pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf pulmonary surfactant (70 mg/kg) within 6 hours after admission (Treatment group 2)
Study: 18819261
Drug: Nifekalant hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Nifekalant (DB16008)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifekalant hydrochloride (NIFE) administration after ICD shock
Study: 18819261
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no NIFE administration)
Study: 16115099
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body protein of E. granulosus (1 mg in 2 ml of PBS with FCA)
Study: 11954900
Drug: Controlled-release formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release formulations (oral and transdermal) for steady pain management and fast-acting, immediate-release formulations for breakthrough pain management.
Study: 11954900
Drug: Individualized opioid
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized opioid treatment based on drug absorption, metabolism, toxicity, and binding characteristics.
Study: 10348790
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 14C-labeled tacrolimus (0.01 mg/kg)
Study: 10348790
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 14C-labeled tacrolimus (0.05 mg/kg)
Study: 6844301
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving no individual treatment, only mass education for non-high-risk individuals.
Study: 31596444
Drug: Low-dose, low-frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, low-frequency oral psoralen-UV-A treatment
Study: 27267880
Drug: High-dose rotigotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rotigotine (≤8 mg/24 h for early PD or ≤16 mg/24 h for advanced PD)
Study: 27267880
Drug: High-dose rotigotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rotigotine
Study: 15627448
Drug: Myringotomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myringotomy with oral antibiotics (Group A)
Study: 15627448
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics without myringotomy (Group B)
Study: 11978141
Drug: 40% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% urea cream (Carmol 40)
Study: 11978141
Drug: 12% ammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% ammonium lactate lotion (Lac‐Hydrin 12%)
Study: 2642440
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5 mg/kg CDC plus 5 mg/kg UDC
Study: 2642440
Drug: UDC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDC alone (10 mg/kg)
Study: 30621974
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + clopidogrel
Study: 20350135
Drug: DRD2/ANKK1 genotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRD2/ANKK1 genotype (TT vs CC)
Study: 16006728
Drug: Prophylactic L-thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic L-thyroxine treatment
Study: 10511942
Drug: Tranilast 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tranilast 0.5% eyedrops, administered 4 times a day for 3 months
Study: 8622101
Drug: Isepamicin 8
Normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 8 mg/kg once daily + ceftazidime 1g twice daily
Study: 8622101
Drug: Amikacin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 7.5 mg/kg twice daily + ceftazidime 2g twice daily
Study: 7299507
Drug: 525 mg
Normalized name: psyllium 525 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 525 mg of ferrous sulfate (105 mg elemental iron) and 500 mg ascorbic acid
Study: 29510372
Drug: Daily fiber
Normalized name: Daily Fiber Sugar-Free
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily fiber intake during an 18-month weight loss intervention
Study: 27325862
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide and methotrexate maintenance (cyclophosphamide 50 mg/day orally continuously and methotrexate 2.5 mg twice/day orally on days 1 and 2 of every week for 1 year)
Study: 27325862
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide and methotrexate maintenance
Study: 18296421
Drug: 1-year trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1-year trastuzumab treatment